Granules India Limited
NSE: GRANULES BSE: GRANULES
NSE
582.40
13.60 (2.39%)
Prev Close
568.8
Open Price
566.1
Volume
850,473
Today Low / High
564.35 / 585
52 WK Low / High
422 / 627
Range
553 - 612
BSE
582.40
13.80 (2.43%)
Prev Close
568.6
Open Price
566.3
Volume
11,590
Today Low / High
566.3 / 585
52 WK Low / High
412.05 / 627.45
Range
553 - 612
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 582.4 (target range: 553 - 612), reflecting a change of 13.6 (2.391%). On the BSE, it is listed at 582.4 (target range: 553 - 612), showing a change of 13.8 (2.42701%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
17 Feb
558.00
1.94%
16 Feb
560.60
0.63%
13 Feb
564.00
-0.29%
12 Feb
577.95
-1.39%
11 Feb
584.00
-0.88%
10 Feb
569.05
2.10%
09 Feb
569.95
-0.17%
06 Feb
576.00
-2.14%
05 Feb
585.00
-0.91%
04 Feb
574.65
1.40%
03 Feb
589.00
-2.92%
02 Feb
552.90
-0.02%
01 Feb
571.80
-3.39%
30 Jan
570.25
0.06%
29 Jan
565.00
1.62%
28 Jan
578.50
-2.35%
27 Jan
588.00
-1.51%
23 Jan
572.00
-1.22%
22 Jan
542.00
5.41%
21 Jan
552.75
-2.75%
Granules India Limited Graph
Granules India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Granules India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 582.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 582.40 | 588.22 | 529.40 - 647.05 |
| 594.05 | 475.24 - 712.86 | ||
| 599.87 | 419.91 - 779.83 | ||
| Bearish Scenario | 582.40 | 576.58 | 518.92 - 634.23 |
| 570.75 | 456.60 - 684.90 | ||
| 564.93 | 395.45 - 734.41 |
Overview of Granules India Limited
ISIN
INE101D01020
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,060,906
Market Cap
138,029,965,661
Last Dividend
1.5
Official Website
IPO Date
2005-06-20
DCF Diff
25.67
DCF
542
Financial Ratios Every Investor Needs
Stock Dividend of GRANULES
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-31 | July 31, 25 | 1.5 | 1.5 | 2025-07-31 | 2025-09-06 | |
| 2024-07-30 | July 30, 24 | 1.5 | 1.5 | 2024-07-30 | 2024-09-05 | |
| 2023-08-03 | August 03, 23 | 1.5 | 1.5 | 2023-08-03 | 2023-09-08 | |
| 2022-07-19 | July 19, 22 | 0.75 | 0.75 | 2022-07-20 | 2022-08-25 | |
| 2022-02-17 | February 17, 22 | 0.25 | 0.25 | 2022-02-18 | 2022-03-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,481.61 Cr | 1,856.18 Cr | 2,625.43 Cr | 0.5858 | 237.68 Cr | 680.47 Cr | 1,705.98 Cr | 501.52 Cr | 20.69 | 930.14 Cr | 0.1119 |
| 2024-03-31 | 4,506.37 Cr | 2,130.71 Cr | 2,375.66 Cr | 0.5272 | 198.56 Cr | 627.31 Cr | 1,545.33 Cr | 405.31 Cr | 16.73 | 847.86 Cr | 0.0899 |
| 2023-03-31 | 4,511.92 Cr | 2,392.28 Cr | 2,119.64 Cr | 0.4698 | 116.38 Cr | 483.45 Cr | 1,516.11 Cr | 516.60 Cr | 21.05 | 913.21 Cr | 0.1145 |
| 2022-03-31 | 3,764.92 Cr | 1,967.72 Cr | 1,797.20 Cr | 0.4774 | 142.97 Cr | 409.34 Cr | 1,241.92 Cr | 412.76 Cr | 16.65 | 726.29 Cr | 0.1096 |
| 2021-03-31 | 3,237.54 Cr | 1,460.80 Cr | 1,776.74 Cr | 0.5488 | 100.31 Cr | 418.47 Cr | 1,251.64 Cr | 549.46 Cr | 22.05 | 864.26 Cr | 0.1697 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 596.38 Cr | 6,252.56 Cr | 2,536.98 Cr | 3,715.5780 Cr | 1,454.76 Cr | 858.38 Cr | 1,342.82 Cr | 2,654.37 Cr | 0.00 Cr | 0.00 Cr | 23.08 Cr | 2,003.1610 Cr |
| 2024-03-31 | 381.10 Cr | 5,520.98 Cr | 2,295.44 Cr | 3,225.5440 Cr | 1,315.06 Cr | 933.96 Cr | 1,300.55 Cr | 2,259.78 Cr | 17.84 Cr | 0.00 Cr | 21.52 Cr | 2,082.2930 Cr |
| 2023-03-31 | 291.56 Cr | 4,904.56 Cr | 2,069.66 Cr | 2,834.9090 Cr | 1,136.24 Cr | 844.68 Cr | 1,149.41 Cr | 1,859.36 Cr | 6.40 Cr | 0.00 Cr | 11.66 Cr | 1,813.5010 Cr |
| 2022-03-31 | 184.71 Cr | 4,512.90 Cr | 1,925.81 Cr | 2,586.5329 Cr | 1,106.31 Cr | 921.60 Cr | 978.55 Cr | 1,595.64 Cr | 6.61 Cr | 0.00 Cr | 22.65 Cr | 1,641.6000 Cr |
| 2021-03-31 | 41.84 Cr | 3,713.45 Cr | 1,540.18 Cr | 2,173.2743 Cr | 849.21 Cr | 807.37 Cr | 782.18 Cr | 1,255.99 Cr | 15.19 Cr | 0.00 Cr | -202.43 Cr | 1,173.0981 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 766.6980 Cr | -694.8820 Cr | 10.9580 Cr | 195.0040 Cr | 207.3850 Cr | 596.3750 Cr | -571.6940 Cr | 501.5160 Cr | 60.0850 Cr | -36.3550 Cr | -20.5690 Cr |
| 2024-03-31 | 439.4140 Cr | -360.1600 Cr | 7.6640 Cr | 58.8380 Cr | 89.5430 Cr | 381.1000 Cr | -380.5760 Cr | 405.3100 Cr | 154.7780 Cr | -36.3060 Cr | -140.7300 Cr |
| 2023-03-31 | 663.6780 Cr | -96.4520 Cr | -519.4700 Cr | 451.8850 Cr | 47.5030 Cr | 181.7460 Cr | -211.7930 Cr | 663.9400 Cr | -47.0920 Cr | -18.6220 Cr | -2.6700 Cr |
| 2022-03-31 | 332.0541 Cr | -380.1149 Cr | 189.9971 Cr | -65.6528 Cr | 142.8775 Cr | 184.7134 Cr | -397.7069 Cr | 557.9983 Cr | 253.0410 Cr | -37.1713 Cr | -184.0266 Cr |
| 2021-03-31 | 432.4778 Cr | -277.1350 Cr | -299.3131 Cr | 161.1362 Cr | -144.0930 Cr | 41.8359 Cr | -271.3416 Cr | 704.3643 Cr | -71.9332 Cr | -24.7208 Cr | -345.8876 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 1,387.94 Cr | 801.04 Cr | 586.90 Cr | 0.4229 | 234.57 Cr | 150.21 Cr | 6.19 | 304.46 Cr | 0.1082 |
| 2025-09-30 | 1,294.67 Cr | 444.96 Cr | 849.72 Cr | 0.6563 | 206.21 Cr | 130.61 Cr | 5.38 | 277.08 Cr | 0.1009 |
| 2025-06-30 | 1,210.11 Cr | 425.07 Cr | 785.04 Cr | 0.6487 | 582.29 Cr | 112.64 Cr | 4.64 | 229.81 Cr | 0.0931 |
| 2025-03-31 | 1,197.43 Cr | 568.86 Cr | 628.57 Cr | 0.5249 | 199.80 Cr | 152.03 Cr | 6.27 | 243.42 Cr | 0.1270 |
| 2024-12-31 | 1,137.70 Cr | 435.68 Cr | 702.02 Cr | 0.6171 | 534.38 Cr | 117.60 Cr | 4.85 | 222.44 Cr | 0.1034 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 608.61 Cr | 17.08 Cr | 625.68 Cr | 760.54 Cr | 1,488.29 Cr | 3,086.88 Cr | 3,313.19 Cr | 6,943.68 Cr | 2,960.90 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 468.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,715.58 Cr |
| 2025-03-31 | 596.38 Cr | 0.00 Cr | 596.38 Cr | 942.22 Cr | 1,342.82 Cr | 3,115.48 Cr | 2,654.37 Cr | 6,252.56 Cr | 2,536.98 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 216.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,427.24 Cr |
| 2024-09-30 | 208.85 Cr | 9.71 Cr | 218.56 Cr | 726.73 Cr | 1,395.44 Cr | 2,605.34 Cr | 2,304.37 Cr | 5,432.70 Cr | 2,005.47 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 112.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 152.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 117.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 97.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 134.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-03-23 | March 23, 15 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,724.40 | ₹4,137,413,222,268.00 | ₹1,262,170.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,283.50 | ₹1,668,071,822,430.00 | ₹438,667.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,210.80 | ₹1,425,126,058,752.00 | ₹347,893.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,280.30 | ₹1,065,937,053,657.00 | ₹689,990.00 |
| Lupin Limited | LUPIN | ₹2,226.70 | ₹1,017,530,525,358.00 | ₹381,509.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹910.05 | ₹915,723,242,600.00 | ₹291,231.00 |
| Mankind Pharma Limited | MANKIND | ₹2,075.60 | ₹856,818,207,443.00 | ₹211,149.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,159.60 | ₹673,497,562,031.00 | ₹3,294,003.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,464.00 | ₹653,303,160,000.00 | ₹83,553.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,030.20 | ₹572,924,082,432.00 | ₹352,142.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,037.45 | ₹560,074,210,996.00 | ₹1,427,154.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,490.60 | ₹378,171,507,351.00 | ₹75,106.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,961.90 | ₹370,046,824,726.00 | ₹85,287.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,984.10 | ₹318,502,704,019.00 | ₹232,902.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,463.00 | ₹277,344,626,020.00 | ₹46,167.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,433.40 | ₹232,916,275,045.00 | ₹569,422.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,886.00 | ₹222,150,000,000.00 | ₹3,172.00 |
| Eris Lifesciences Limited | ERIS | ₹1,344.60 | ₹183,157,231,639.00 | ₹30,605.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,620.00 | ₹174,743,088,180.00 | ₹43,615.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹890.50 | ₹159,497,339,235.00 | ₹1,067,406.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹775.30 | ₹152,395,390,037.00 | ₹34,929.00 |
| Granules India Limited | GRANULES | ₹582.40 | ₹141,330,260,198.00 | ₹850,473.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹889.50 | ₹140,869,890,846.00 | ₹92,618.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,711.50 | ₹130,094,017,704.00 | ₹114,514.00 |
| Cohance Lifesciences Limited | COHANCE | ₹325.85 | ₹124,659,502,569.00 | ₹9,235,891.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹899.10 | ₹110,351,937,600.00 | ₹21,088.00 |
| Viyash Scientific Limited | VIYASH | ₹223.97 | ₹97,696,959,049.00 | ₹538,456.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,018.00 | ₹83,295,698,876.00 | ₹7,438.00 |
| Strides Pharma Science Limited | STAR | ₹877.10 | ₹80,844,687,449.00 | ₹365,132.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹487.85 | ₹74,690,838,995.00 | ₹431,045.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹721.90 | ₹65,438,278,651.00 | ₹93,098.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹328.80 | ₹64,307,301,101.00 | ₹186,914.00 |
| FDC Limited | FDC | ₹379.15 | ₹61,729,443,349.00 | ₹58,724.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹132.21 | ₹42,904,999,149.00 | ₹351,056.00 |
| Innova Captab Limited | INNOVACAP | ₹687.90 | ₹39,365,028,659.00 | ₹16,454.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹340.75 | ₹37,129,914,049.00 | ₹403,562.00 |
| Suven Life Sciences Limited | SUVEN | ₹152.55 | ₹34,701,158,700.00 | ₹141,838.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹374.25 | ₹34,157,797,500.00 | ₹79,614.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹664.25 | ₹33,690,165,496.00 | ₹20,221.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,945.90 | ₹32,183,269,289.00 | ₹10,368.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹295.65 | ₹29,648,522,899.00 | ₹45,302.00 |
Key Executives
Senior VP and Head Formulation R&D
Manikandan Ramalingam
Gender: Not Specified
Year Born:
President - Head API Manufacturing & Operations
N. Baskaran
Gender: Not Specified
Year Born:
Chief Technology Officer and Head of R&D
V. Srinivas
Gender: Not Specified
Year Born: 1966
President & Global Head of Quality
Rajesh Kapoor
Gender: Not Specified
Year Born:
Chief Human Resources Officer
Atul Dhavle
Gender: male
Year Born: 1970
VP & Head of IT
Krishna Mohan
Gender: male
Year Born:
Executive Director
Harsha Chigurupati
Gender: male
Year Born: 1983
Chief Financial Officer
Mukesh Surana
Gender: male
Year Born: 1981
President & Head of Formulations Operations
Ramraj Rangarajalu
Gender: male
Year Born:
President and Chief Strategy & Sustainability Officer
Sanjay Kumar
Gender: male
Year Born:
Company Secretary & Compliance Officer
Chaitanya Tummala
Gender: female
Year Born:
Head of Marketing & Executive Director
Priyanka Chigurupati
Gender: female
Year Born:
Chairman & MD
Krishna Prasad Chigurupati
Gender: Not Specified
Year Born: 1954
FAQs about Granules India Limited
Who is the CEO of the company?
The CEO is Krishna Prasad Chigurupati.
What is the current market price of the stock?
The current price is ₹568.80.
What is the 52-week price range?
The range is ₹422-627.
What is the market capitalization of the company?
The market capitalization is ₹13,803.00 crores.
What is the dividend yield?
The dividend yield is 0.26%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 25.30.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Granules India Limited (ISIN: INE101D01020) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹13,803.00 crores and an average daily volume of 1,060,906 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.5.